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OBJECTIVE: Obstructive sleep apnea syndrome is associated with cardiovascular diseases and thromboembolic
events. The mean platelet volume (MPV) is a predictor of cardiovascular thromboembolic events. The aim of the
present study is to investigate the association between the MPV and disease severity in patients with obstructive
sleep apnea syndrome.
METHODS: We prospectively included 194 obstructive sleep apnea syndrome patients without cardiovascular
disease (mean age 56.5±12.5 years) who were undergoing sleep tests. An overnight full laboratory
polisomnography examination was conducted on each patient. The patients were divided into 3 groups
according to the apnea-hypopnea index (AHI): (1) AHIlow group: 5pAHIo15, (2) AHImid group: 15oAHIp30,
and (3) AHIhigh group: AHI430.
RESULTS: The highest MPV values were found in the AHIhigh group compared with other groups (po0.05 for
all). Multiple linear regression analysis indicated that the MPV was associated with the AHI (b=0.500, po0.001)
and the high sensitivity C-reactive protein (hs-CRP) level (b=0.194, p=0.010).
CONCLUSION: The MPV is independently associated with both disease severity and inflammation in patients
with obstructive sleep apnea syndrome.
KEYWORDS: Obstructive sleep apnea; Apnea-hypopnea index; Mean platelet volume; High sensitivity
C-reactive protein.
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’ INTRODUCTION
Obstructive sleep apnea syndrome (OSA) is a common
sleep-related respiratory disorder that is characterized by
repeated episodes of apnea and hypopnea due to intermittent
upper airway obstruction. OSA, which is associated with
repetitive nocturnal arterial oxygen desaturation and hyper-
capnia as well as with alterations in systemic and pulmonary
arterial pressure (1) is a highly prevalent illness that affects 4%
of middle-aged men and 2% of middle-aged women (2).
Furthermore, OSA is well known as an independent risk
factor for cardiovascular diseases (CVDs) and hypertension
(HT) (1,3). Several possible mechanisms such as sympathetic
nervous system activation, endothelial dysfunction, intermit-
tent hypoxia, oxidative stress and inflammation explain the
increased CVD prevalence in OSA patients (4). Although
augmented hypercoagulability has been demonstrated in OSA
patients who are not receiving continuous positive airway
pressure (CPAP) therapy (5), the exact mechanism that drives
the association between OSA and hypercoagulability is
unknown. Moreover, few studies have investigated the asso-
ciation between OSA severity and hypercoagulability (6). In a
previous study, OSA was found to be associated with both
arterial and venous thromboembolism (7).
The mean platelet volume (MPV) is a marker of
thrombocyte activation and plays a pivotal role in the
pathogenesis of CVDs (8,9). Larger platelets contain more
granules and thromboxane A2 and express more glycopro-
tein Ib and IIb/IIIa receptors; these platelets thus aggregate
more quickly and strongly to collagen, possibly leading to
increased thromboembolic events (10-12).DOI: 10.6061/clinics/2015(07)04
Copyright & 2015 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial
use, distribution, and reproduction in any medium, provided the original work is
properly cited.
481
CLINICAL SCIENCE
Increased MPVs have been found in hypertension,
hypercholesterolemia, diabetes mellitus, acute myocardial
infarction and acute ischemic stroke (11). Although a few
studies have reported a relationship between OSA and
increased platelet activation (15,16), the number of studies
investigating the association between OSA and MPV is
limited (17,18). The main purpose of the present study is to
investigate the association between the MPV and the OSA
severity in patients without CVD or hypertension and who
do not take any medications that may affect platelet
functions.
’ METHODS
Subjects who were clinically suspected of having sleep-
related disorders (severe snoring, daytime sleepiness, and
witnessed apnea) and who underwent a sleep test between
March 2012 and July 2014 were prospectively enrolled in our
study. A total of 194 patients (148 males; mean age 56.5±12.5
years) with an AHIX5 were included. All of the data were
collected prior to the administration of any treatment for
OSA. After collecting a detailed medical history and
performing a complete physical examination, each partici-
pant was questioned regarding major cardiovascular risk
factors, including age, sex, diabetes mellitus (DM), smoking
status and hypertension (HT). Additionally, systolic blood
pressure (SBP), diastolic blood pressure (DBP) and initial
heart rate were recorded. Each of the patients underwent
electrocardiography (ECG) and comprehensive transthoracic
echocardiography. Patients with atherosclerotic heart disease
such as coronary artery disease, cerebrovascular accident
and peripheral vascular disease, heart failure, diabetes,
hypertension, and hyperlipidemia and patients who were
taking medications associated with these conditions were
excluded. Patients with central sleep apnea syndrome, upper
airway resistant syndrome, narcolepsy, or movement dis-
order were excluded. Patients using any drug (such as
aspirin, clopidogrel, dipyridamole, heparin, aminophylline,
verapamil, nonsteroidal anti-inflammatory drugs, corticos-
teroid, furosemide, antibiotics, and alcohol) that could affect
platelet function were also excluded. Informed consent was
obtained for each participant, and the local ethics committee
approved the study protocol.
OSA diagnosis of and sleep testing
An overnight full laboratory polysomnography examination
was conducted on each subject. All sleep recordings (E-Series,
Compumedics, Melbourne, Australia) included electroencepha-
lography, electrooculography, submental electromyography,
and oxygen saturation (pulse oximetry), respiratory movement
(inductance plethysmography), and nasal and oral airflow
measurements. Sleep staging and sleep-disordered breathing
were subsequently scored using standard techniques (19) but
with all hypopneas including a mandatory minimum 4%
oxygen desaturation. The average numbers of apnea and
hypopnea episodes per hour of sleep were measured as the
AHI. Patients were classified into 3 separate groups to
determine the OSA severity according to their AHI scores, as
follows: AHImild group (5oAHIo15), AHImoderate group
(15pAHIo30), and AHIsevere group (AHIX30).
Echocardiography
All echocardiographic examinations were performed using
commercially available equipment (Vivid-7; GE Vingmed
Sound, Horten, Norway) with a 2.5–3.5 MHz transducer.
A single echocardiographer who was blinded to the patients’
clinical and laboratory data interpreted each echocardio-
graphic examination independently. Simultaneous ECG
recordings were also obtained. All patients were examined
at rest in the left lateral decubitus position. Echocardio-
graphic techniques and calculations of different cardiac
dimensions were performed in accordance with the recom-
mendations of the American Society of Echocardiography.
The left ventricular ejection fraction (EF) was calculated
using a modified Simpson’s rule technique (20).
Laboratory Analysis
Fasting venous blood samples on admission were obtained
from all patients to determine their plasma fasting blood
glucose, total cholesterol, high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycer-
ide, creatinine, and high-sensitivity CRP (hs-CRP) levels and
blood counts. Blood samples were collected through the brachial
vein into tubes containing dipotassium EDTA. Serum creatinine,
fasting glucose, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and lipid profiles were measured using
an autoanalyzer (Roche Diagnostics Modular Systems, Tokyo,
Japan). To measure hematologic parameters, platelet counts and
MPVs, samples were analyzedwithin 20 minutes after collection
using a Sysmex XT 1800i automated hematology analyzer
(Roche Diagnostics, Shanghai, China). For the MPV, the cut-off
value was 9-13 fL, and the intra- and inter-assay coefficients of
variation (CVs) were below 4.1% and 7.1%, respectively.
Statistical Analysis
All analyses were conducted using SPSS 17.0 (SPSS for
Windows 17.0, Chicago, IL, USA). Data were expressed as the
mean ± SD. A comparison of categorical variables between
groups was performed using a chi-square test. Analysis of
variance (ANOVA) was applied to analyze continuous
variables between the AHI groups. Normality analysis was
performed using a Kolmogorov–Smirnov test. Associations
between other variables and the AHI were assessed by
Pearson’s correlation coefficient. Multiple linear regression
analysis was performed to identify independent associations
of the AHI by including the parameters that were correlated
with the AHI in the bivariate analysis. Standardized b
regression coefficients and their significance according to
multiple linear regression analysis were reported. A p-value of
o0.05 was considered statistically significant.
’ RESULTS
A total of 194 patients who fulfilled the selection criteria
were included in the analysis. The patients were divided into
three groups according to their corresponding AHI values:
(a) AHImild group, 62 patients (5oAHIo15); (b) AHImoderate
group, 61 patients (15pAHIo30); and (c) AHIsevere group,
71 patients (30pAHI). The mean AHI values were 9.0±2.7,
22.9±4.0 and 56.6±20.1 for the mild, moderate and severe
groups, respectively. Of the 194 participants, 148 (76%) were
men, and 46 (24%) were women; the mean age was 56.5 ±
12.5 years. No significant differences were found between the
groups in terms of age and sex.
Baseline characteristics. Body mass index (BMI) was
higher in the AHIsevere group than in the AHImoderate and
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AHImild groups (po0.05 for both). Additionally, systolic
blood pressure was higher in the AHImoderate and AHIsevere
groups compared with the AHImild group (po0.05 for both).
Laboratory findings. Total cholesterol, LDL cholesterol
and hs-CRP levels were higher in the AHIsevere group
compared with the AHImoderate and AHImild groups
(po0.05 for all). Platelet counts were lower in the AHImild
group than in the AHImoderate and AHIsevere groups (po0.05
for both). The highest MPVs were observed in the AHIsevere
group compared with the AHImoderate and AHImild groups
(po0.05 for all). Moreover, the MPV was higher in the
AHImoderate group than in the AHImild group (po0.05).
MPVs according to the AHI groups are shown in Table 1.
Sleep test findings. Higher oxygen desaturation index
(ODI) values were observed in the AHIsevere group than in
the AHImoderate and AHImild groups (po0.05 for both).
Bivariate and multivariate relationships of the mean
platelet volume. According to the results of bivariate
analysis, the MPV was associated with the BMI (r=0.167,
p=0.020), SBP (r=0.355, po0.001), total cholesterol levels
(r=0.224, p=0.002), hs-CRP levels (r=0.189, p=0.011), the
platelet count (r=-0.360, po0.001), the ODI (r=0.557,
po0.001) and the AHI (r=0.683, po0.001). The relationship
between the AHI and MPV is shown in Table 2.
Multiple linear regression analysis showed that the MPV
was associated with hs-CRP levels (b=0.194, p=0.010), the
platelet count (b=-0.188, p=0.014) and the AHI (b=0.500,
po0.001).
’ DISCUSSION
The present study shows that MPV is independently
associated with both the disease severity, as indicated by the
AHI, and inflammation in OSA patients. Our study also
suggests that MPV might play a role in thromboembolic
events in OSA patients with severe AHI.
Although several previous studies have demonstrated that
OSA is associated with CVD, the mechanism behind this
association remains controversial (1,3,21). Of all of the health
consequences of OSA, those that affect the cardiovascular
system are the most undesirable, and platelet activation
plays a pivotal role in CVD (18). Individual characteristics
such as advanced age, increased blood pressure and obesity
are the primary risk factors for both CVD and OSA (22).
Table 1 - Baseline characteristics and laboratory, echocardiographic and sleep test findings.
Variables AHIlow group
(5oAHIo15)
AHImid group
(15pAHIo30)
AHIhigh group
(AHIX30)
P-value
Baseline characteristics
Age (years) 45.5±11.2 46.2±11.7 46.5±10.8 0.882
BMI (kg/m2) 30.0±5.5 30.1±3.6 32.1±3.6a 0.007
Gender (male) 43 (69.4%) 48 (78.7%) 57 (80.3%) 0.291
SBP (mmHg) 113.2±10.9b 118.2±10.1 122.3±9.4 0.002
DBP (mmHg) 73.9±5.7 75.4±6.1 76.1±6.3 0.345
Smoking, n (%) 26 (41.9%) 26 (42.6%) 31 (43.7%) 0.841
Laboratory findings
Glucose (mg/dl) 93.2±8.5 92.7±9.1 92.7±8.4 0.944
Total cholesterol (mg/dl) 174.5±28.4 172.9±24.4 190.5±35.0c 0.001
Triglycerides (mg/dl) 176.8±68.4 183.0±70.0 180.9±84.4 0.898
HDL cholesterol (mg/dl) 41.6±10.1 39.6±9.7 40.0±11.7 0.558
LDL cholesterol (mg/dl) 115.2±33.5 111.7±25.8 128.7±29.4d 0.003
WBCs 8.4±2.4 7.8±1.8 8.2±2.0 0.260
Hemoglobin (mg/dl) 14.6±1.5 14.5±1.6 14.7±1.3 0.914
Platelet count 282.4±59.4e 261.3±54.3 245.3±51.3 0.001
MPV 9.4±1.1f 9.9±1.0ff 11.4±1.3 o0.001
Creatinine (mg/dl) 0.80±0.13 0.79±0.17 0.81±0.14 0.986
Hs-CRP 0.62±0.28 0.68±0.32 0.83±0.40g 0.010
Echocardiography
LAD (mm) 34.0±4.6 33.0±3.4 34.3±4.5 0.280
LVID (mm) 48.0±3.3 46.3±6.0 47.0±6.7 0.528
EF (%) 65.6±4.1 65.6±4.6 66.6±4.9 0.524
Sleep test findings
AHI 9.0±2.7i 22.9±4.0ff 56.6±20.1 o0.001
ODI 11.3±18.3 15.8±9.8 54.2±29.3h o0.001
Apnea index 5.6±16.8 8.4±8.6 41.3±28.0 o0.001
Hypopnea index 5.0±4.8 7.7±7.2 13.2±12.6 0.001
ap=0.006 vs. AHIlow group, p=0.008 vs. AHImid group
bP=0.05 vs. AHImid group, po0.001 vs. AHIhigh group
cp=0.003 vs. AHIlow group, p=0.001 vs. AHImid group
dp=0.010 vs. AHIlow group, p=0.001 vs. AHImid group
eP=0.034 vs. AHImid group, po0.001 vs. AHIhigh group
f P=0.010 vs. AHImid group, po0.001 vs. AHIhigh group
ffpo0.001 vs. AHIhigh group
gp=0.005 vs. AHIlow group, p=0.026 vs. AHImid group
iPo0.001 vs. AHImid group and AHIhigh group
hpo0.001 vs. AHIlow group and AHImid group
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Likewise, markers of inflammation such as Hs-CRP are
elevated in patients with OSA and CVD (17,22,23).
The present study shows that MPV is associated with
disease severity in OSA patients. The relationship between
OSA and the MPV has been previously investigated in a
limited number of studies (17,18). A recent study assessed
the relationship between OSA severity and the MPV in 205
OSA patients and found that MPV was higher in patients
with moderate and severe OSA (17). However, the patients
with moderate or severe OSA in that study were more likely
to be hypertensive and active smokers, and in contrast to our
study, the authors did not exclude patients with these
cardiovascular risk factors, which may have influenced the
MPV. In a similar study, Varol et al. investigated the effects of
OSA on the MPV in hypertensive patients and active
smokers (18); however, there were several differences
compared with our study. First, we included a larger
population of study subjects. Second, we excluded patients
who had disorders or received medications that could affect
the MPV. The exact mechanism for the association between
OSA and the MPV is not known. Several possible mechan-
isms might be responsible for this relationship, including
sympathetic nervous system activation due to repetitive
nocturnal hypoxemia, increased inflammation and oxidative
stress and increased cardiovascular risk factors such as
hypertension and obesity (4,24). In the present study,
patients with cardiovascular risk factors such as hyperten-
sion and diabetes were excluded from the study. It is well
known that the MVP increases with hypoxemia (24).
Additionally, the relationship between the MPV and hs-
CRP in the present study confirms the effect of inflammation
on platelet activation in OSA patients. However, the relation-
ship between the MPV and oxidative stress was not
investigated in the present study. Therefore, repetitive
nocturnal hypoxemia and increased inflammation may be
responsible for the increased MPV in patients with severe
OSA.
Previous studies have demonstrated that MPV is a marker
of inflammation in various clinical conditions (25,26). CRP is
also a well-known marker of inflammation, and increased
CRP levels are associated with atherothrombic events (27).
Moreover, low-grade inflammation exists in patients with
non-dipper HT, and the MPV is correlated with CRP levels
(28). In a previous study, Panautsoulos et al. observed a
significant decrease in CRP levels after nasal CPAP treatment
in OSA patients (29). In the present study, we demonstrated
that both hs-CRP and MPV are correlated with the OSA
severity, as determined by the AHI. Using bivariate and
multivariate analyses, we confirmed the association between
the MPV and hs-CRP levels. Because we excluded patients
with clinical conditions that may alter the MPV, the
relationship between the MPV and AHI identified in this
study is more reliable.
There are some notable limitations to our current study,
the most prominent of which is the absence of a control
group without OSA. However, it has been previously
demonstrated that OSA patients exhibit increased platelet
activation and higher MPVs compared with controls.
Because the main purpose of our study was to investigate
the association between the MPV and the OSA severity,
we did not include a control group. Additionally, we did
not prospectively follow the patients and did not investigate
the effects of various treatments such as nasal CPAP
treatment on MPVs. However, this study was designed to
demonstrate a relationship between the MPV and OSA
severity.
In conclusion, the findings of our current study demon-
strated that the MPV, a marker of cardiovascular disease, and
hs-CRP, a marker of systemic inflammation, are both
significantly associated with the OSA severity. Additional
large-scale studies should be designed to explore the possible
mechanisms of this relationship and to assess alterations in
platelet activation and the MPV in response to adequate OSA
treatment.
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